Gland Pharma Limited has informed the Exchange that Record date for the purpose of Dividend is 11-Aug-2026.
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gland Pharma's Board has approved Q4 and full year FY26 results showing consolidated revenue of Rs. 64,307 million (up 14.5% YoY) and net profit of Rs. 4,373 million (up 20% YoY). The company recommended a final dividend of Rs. 20 per equity share (2000% on Rs. 1 face value) for FY26, subject to shareholder approval at the 48th AGM on August 25, 2026. The record date for determining dividend eligibility is August 11, 2026. EPS improved from Rs. 42.40 in FY25 to Rs. 62.35 in FY26. An exceptional charge of Rs. 243.46 million was recorded due to new labour code implementation. Auditors issued unmodified opinions on the financial statements.
The strong 20% profit growth and increased dividend payout signal financial health and confidence in future prospects. Shareholders on record as of August 11, 2026 will be eligible to receive Rs. 20 per share dividend, which is positive for investor returns.